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Helicases are among the first enzymes to encounter
DNA damage during DNA processing within the cell and
thus are likely to be targets for the adverse effects of DNA
lesions induced by environmental chemicals. Here we ex-
amined the effect of cis- and trans-opened 3,4-diol 1,2-
epoxide (DE) DNA adducts of benzo[c]phenanthrene
(BcPh) at N6 of adenine on helicase activity. These ad-
ducts are derived from the highly tumorigenic ()-
(1R,2S,3S,4R)-DE as well as its less carcinogenic ()-
(1S,2R,3R,4S)-DE enantiomer in both of which the
benzylic 4-hydroxyl group and epoxide oxygen are trans.
The hydrocarbon portions of these adducts intercalate
into DNA on the 3 or the 5 side of the adducted deoxya-
denosine for the 1S- and 1R-adducts, respectively. These
adducts inhibited the human Werner (WRN) syndrome
helicase activity in a strand-specific and stereospecific
manner. In the strand along which WRN translocates,
cis-opened adducts were significantly more effective in-
hibitors than trans-opened isomers, indicating that WRN
unwinding is sensitive to adduct stereochemistry. WRN
helicase activity was also inhibited but to a lesser extent
by cis-opened BcPh DE adducts in the displaced strand
independent of their direction of intercalation, whereas
inhibition by the trans-opened stereoisomers in the dis-
placed strand depended on their orientation, such that
only adducts oriented toward the advancing helicase in-
hibited WRN activity. A BcPh DE adduct positioned in the
helicase-translocating strand did not sequester WRN, nor
affect the rate of ATP hydrolysis relative to an unad-
ducted control. Although the Bloom (BLM) syndrome he-
licase was also inhibited by a cis-opened adduct in a
strand-specific manner, this helicase was not as severely
affected as WRN. Because BcPh DEs form substantial
amounts of deoxyadenosine adducts at dA, their adverse
effects on helicases could contribute to genetic damage
and cell transformation induced by these DEs. Thus, the
unwinding activity of RecQ helicases is sensitive to the
strand, orientation, and stereochemistry of intercalated
polycyclic aromatic hydrocarbon adducts.
Helicases are enzymes that disrupt complementary strands
of duplex DNA in a reaction dependent on nucleoside-5-
triphosphate hydrolysis (1–3). Evidence suggests that helicases
play important roles in DNA metabolism, and a growing num-
ber of helicases have been linked to human disease (4, 5).
Pathways of DNA replication, recombination, and repair are
affected by DNA lesions, and the effects of helicases on such
pathways are probably modulated by their interactions with
chemically modified DNA. Although the mechanism for DNA
unwinding has been studied for several helicases (reviewed in
Refs. 1–3), very little is known regarding how specific co-
valently linked adducts affect helicase function.
RecQ helicases are believed to function in repairing replica-
tion forks that have been stalled by DNA damage and may also
play a role in the intra-S-phase checkpoint, which delays the
replication of damaged DNA, thus permitting repair to occur
(6). Only limited information is available pertaining to the
mechanism of DNA unwinding by RecQ helicases, and no crys-
tallographic data are currently available. Biochemical studies
of the prototype member, Escherichia coli RecQ helicase, indi-
cate that the enzyme utilizes multiple interacting ATP-binding
sites to unwind double-stranded DNA (7). The human WRN
gene product, which is defective in the premature aging disor-
der Werner syndrome, encodes a 1,432 amino acid protein with
the seven conserved motifs found in the RecQ family of Super-
family 2 DNA helicases (8). WRN1 (9), similar to all of the other
RecQ helicases characterized to date, is a 3–5-helicase (re-
viewed in Refs. 4 and 10). Thus, WRN is thought to translocate
3–5 along the bound single-stranded DNA residing between
the duplex portions of a helicase directionality substrate. How-
ever, unidirectional translocation of WRN on a DNA lattice
remains to be demonstrated. Although the DNA substrate spec-
ificity of WRN (11) and other RecQ helicases (12, 13) has been
studied, the effects of DNA damage on helicases of this family
have not been characterized prior to this study.
The replication (14–17) and recombination (18–20) defects
observed in WRN/ cells may reflect abnormal processing of
specific structures associated with the replication fork or a
DNA recombination intermediate. Our recent work demon-
strated that WRN helicase is able to unwind a synthetic repli-
cation fork in the direction of the fork (11), a biochemical
activity that may be important for the maintenance of fork
progression. WRN was recently shown to interact functionally
with DNA polymerase  by stimulating the enzymatic rate of
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nucleotide incorporation (21). It was subsequently shown that
WRN facilitates polymerase  synthesis through hairpin and
tetraplex structures that impede the polymerase, suggesting
that WRN may remove secondary structure at a stalled repli-
cation fork to allow polymerase  synthesis to proceed (22). The
results to be reported here suggest that WRN may not function
properly to ensure replication fork progression if the fork is
blocked by a covalent DNA adduct, even though WRN may
disrupt other DNA structures such as tetraplexes (13, 23) or
triplexes (24) that might impede a replication fork.
Polycyclic aromatic hydrocarbon (PAH) 3,4-diol 1,2-epoxide
(DE)-DNA adducts have been used by us as tools to probe the
interactions between other DNA-processing enzymes such as
topoisomerases (25, 26) and their DNA substrates as well as to
elucidate possible molecular mechanisms for the induction of
cancer by these DNA lesions. In this study, we examined the
effects of site-specific benzo[c]phenanthrene (BcPh) DE ad-
ducts at N6 of deoxyadenosine (Scheme I) positioned centrally
in the double-stranded region of a forked DNA duplex substrate
on the unwinding activity catalyzed by WRN helicase. These
adducts are derived by both cis- and trans-opening of the ()-
(1R,2S,3S,4R)- and ()-(1S,2R,3R,4S)-enantiomers of the DE
in which the benzylic 4-hydroxyl group and epoxide oxygen are
trans. The DEs are examples of mutagenic and carcinogenic
bay-region diol epoxide metabolites that are formed from PAH
by the combined action of cytochrome P-450 and epoxide hy-
drolase (27, 28). Benzo[c]phenanthrene is a common environ-
mental contaminant (29–33), which has been found in indus-
trial emissions, wastewater, and food. Metabolism of the
hydrocarbon on mouse skin (34) by cultured rodent embryo
cells (35) or by human mammary carcinoma cells (34) led to
covalent BcPh DE-DNA adducts primarily at deoxyadenosine
(dA). Notably, human liver microsomes metabolize BcPh via
the carcinogenic diol epoxide pathway to a greater extent than
do microsomes from rat liver (36). The metabolically derived
BcPh DEs react extensively with dA residues in DNA in vitro
(37) and in vivo (38), and induce mutations at dA in mamma-
lian cells (39). Such mutations provide an attractive mecha-
nism for the induction of cell transformation leading to cancer.
In particular the ()-(1R,2S,3S,4R)-BcPh DE is one of the most
tumorigenic PAH DEs identified to date (40).
A particularly useful feature of the PAH DEs is the variety of
structural motifs exhibited by the different DE adducts within
duplex DNA. These structural motifs have been well charac-
terized by NMR studies. The aromatic portions of the 1R and
1S trans-opened BcPh DE N6-dA adducts used in this study
(see Fig. 1) intercalate between adjacent base pairs in duplex
DNA (41, 42). Local stretching of the double helix accommo-
dates the intercalated aromatic rings, and the adducted ade-
nine retains Watson-Crick base pairing to its complement
within the helix despite some buckling and propeller twisting
of the adducted base pair. The non-aromatic benzo-rings are
situated in the major groove, and the intercalated aromatic
portion projects toward but not into the minor groove. These
trans-opened BcPh DE-dA adducts are oriented such that the
aromatic moiety of the 1R dA adduct intercalates on the 5 side
of the adducted adenine base, whereas the aromatic moiety of
the 1S dA adduct intercalates on the 3 side (41, 42). Although
the solution structures of cis-opened BcPh DE-dA adducts in
DNA have not been determined by NMR, the two cis-adducts in
the present study are likely to exhibit the same dependence of
the direction of intercalation on their configuration at C-1 as
their trans-analogs.
The present study demonstrates that cis- and trans-opened
BcPh DE-dA adducts in DNA are highly effective probes of
helicase activity. The cis-S BcPh DE-dA adduct in the strand
on which WRN is presumed to translocate was a potent inhib-
itor of unwinding activity, but a forked duplex containing this
adduct did not sequester WRN to any greater extent than an
unmodified control. The trans-S adduct was not as effective as
the cis-S isomer in inhibiting translocation. Inhibition of un-
winding activity is also sensitive to the orientation of the ad-
duct (toward or away from the advancing helicase) in the dis-
placed strand of the duplex region, which is opposite to the
strand on which the helicase translocates.
MATERIALS AND METHODS
Proteins—Recombinant hexahistidine-tagged WRN protein (wild-
type, WRN-E84A) was overexpressed using a baculovirus/Sf9 insect
system and purified as described previously (43). UvrD (DNA helicase
II) was overexpressed in Escherichia coli and purified as described
previously (44). Purified recombinant hexahistidine-tagged BLM pro-
tein (45) was kindly provided by Dr. Ian Hickson (University of Oxford).
T4 polynucleotide kinase was obtained from New England Biolabs.
Nucleotides, Oligonucleotides, and DNA Substrates—[3H]ATP was
from Amersham Biosciences, and [-32P]ATP was from PerkinElmer
Life Sciences. The oligonucleotides used for preparation of duplex DNA
substrates are listed in Table I. Unadducted oligonucleotides were
purchased from Lofstrand Technologies or Midland Certified Reagent
Company. Oligonucleotide 25-mers containing diastereomerically pure
cis- and trans-opened BcPh DE-dA adducts (Scheme I) were synthesized
as their 5-phosphates using a semi-automated procedure, essentially
as described previously (Ref. 46 and references therein), with a manual
step for coupling of the BcPh DE-dA-adducted phosphoramidites (47) as
a mixture of their 1R/1S diastereomers. For details of the syntheses and
chromatographic separation of the diastereomeric R/S pairs of cis- and
trans-adducted oligonucleotides, see Supplemental Data. Absolute con-
figurations were assigned to the separated (1R and 1S) oligonucleotide
diastereomers by enzymatic hydrolysis (48) to the nucleoside adducts
whose circular dichroism (CD) spectra were then compared with the
known CD spectra (49) of the optically active BcPh DE-dA adducts.
DNA duplex substrates were prepared as described previously (11) and
are shown in Table II.
Helicase Assays—Helicase assay reaction mixtures (20 l) contained
30 mM Hepes (pH 7.6), 5% glycerol, 40 mM KCl, 0.1 mg/ml bovine serum
albumin, 8 mM MgCl2, 2 mM ATP, 10 fmol of DNA duplex substrate (0.5
nM DNA substrate concentration), and the indicated concentrations of
WRN, BLM, or UvrD. Helicase reactions were initiated by the addition
of the respective helicase and then incubated at 37 °C for 15 min.
Reactions were quenched with 10 l of loading buffer (50 mM EDTA,
40% glycerol, 0.1% bromphenol blue, 0.1% xylene cyanol) containing a
10-fold excess of unlabeled oligonucleotide with the same sequence as
the labeled strand. The products of the helicase reactions were resolved
on nondenaturing 12% (19:1 acrylamide: bisacrylamide) polyacrylamide
gels. Radiolabeled DNA species in polyacrylamide gels were visualized
SCHEME 1. Structures of the optically active BcPh DE and their
N6-dA adducts, where A represents the adenine base. The par-
tially saturated benzo-ring of the DE that is the site of covalent attach-
ment to the base is shown in boldface. Note that the absolute configu-
ration at C-1 is retained on cis-opening and inverted on trans-opening
of each DE.
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using a PhosphorImager and quantitated using the ImageQuant soft-
ware (Molecular Dynamics). The percent helicase substrate unwound
was calculated by the formula: percent unwinding  100  (P/(S  P)),
where P is the product and S is the residual substrate. The values of P
and S have been corrected after subtracting background values in
controls containing no enzyme and heat-denatured substrate, respec-
tively. Helicase data represent the mean of at least three independent
experiments with mean  S.D. shown by error bars.
For helicase sequestration studies, WRN (3.6 nM, 72 fmol) was pre-
incubated with the indicated amounts (0–500 fmol) of “unlabeled” sin-
gle-stranded DNA (oligonucleotides unadducted A or adducted E) or
“unlabeled” forked-duplex DNA molecules (substrates 1-unadducted or
5-cis-S) in standard helicase reaction buffer (described above) contain-
ing 2 mM ATP for 3 min at 24 °C. 10 fmol of radiolabeled forked-duplex
molecule (11-tracker) was subsequently added to the reaction mixture
and incubated for 7 min at 37 °C. Reactions were then quenched and
resolved on native polyacrylamide gels as described above. Typically,
75–90% of the tracker-11 helicase substrate was unwound in reactions
lacking the competitor DNA molecule. Displacement (% Control) is
expressed relative to the control reactions lacking the competitor DNA.
ATPase Assays—ATPase assay reaction mixtures (30 l) contained
30 mM Hepes (pH 7.6), 5% glycerol, 40 mM KCl, 0.1 mg/ml bovine serum
albumin, 8 mM MgCl2, the indicated duplex DNA effector concentration,
0.8 mM [3H]ATP, and 55 nM WRN. Reactions were initiated by the
addition of WRN and incubated at 37 °C. Samples (5 l) were removed
at 2-min intervals and evaluated by thin layer chromatography as
described previously (50). 20% of the substrate ATP was consumed in
the reaction over the entire time course (10 min) of the experiments. Keff
values (Table III) were determined using linear regression analysis
from double reciprocal plots of ATP hydrolysis initial rate versus forked-
duplex DNA effector concentration (Fig. 4).
RESULTS
To understand better the effects of DNA structural elements
on WRN-unwinding activity, we investigated how the helicase
is affected by a series of structurally related single covalent
DNA adducts. Specifically, the helicase substrates are forked
DNA duplexes with a covalently bonded site-specific BcPh DE
adduct in one of the two DNA strands (Table I) and positioned
centrally in the 20-mer duplex region (Table II). For the pur-
poses of this study, the stereochemistry and position of the
adduct within the DNA duplex were varied. In the first class of
substrates (Table II, substrates 1–5 with a 5-nucleotide 3-
unduplexed tail), the adduct is positioned within the shorter
25-mer strand on which WRN is presumed to 3–5 translocate.
The second class of substrates (Table II, substrates 6–10 with
a 25-nucleotide 3-unduplexed tail) contains the same adducts
as the first class, but the adduct is on the 25-mer strand
opposite to the 45-mer strand on which WRN translocates.
Because the forked-duplex substrates used in this study con-
tain a relatively short duplex tract (20 bp), we were able to
study WRN helicase activity by measuring the release of the
labeled intact 45-mer in the absence of an auxiliary factor such
as replication protein A. Our choice of forked-duplex DNA
substrates harboring a site-specific BcPh DE adduct enabled us
to assess the effects of adduct stereochemistry, orientation, and
strand occupation on WRN helicase activity.
Inhibition of WRN Helicase Activity by a Single BcPh DE-dA
TABLE I
Oligonucleotide sequences for DNA substrates
Benzo[c]phenanthrene DEs are covalently bonded to deoxyadenosine with the marker indicating the orientation of the intercalated hydrocarbon
relative to the adducted base. For structures of the adducts, see Scheme I.
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Adduct in the Strand on Which WRN Translocates—We first
tested helicase substrates with the single BcPh DE-dA adduct
positioned centrally in the duplex tract on the strand on which
WRN translocates (substrates 1–5). For all of the five sub-
strates tested, the percent duplex DNA substrate unwound
depended on the concentration of WRN present in the reaction
(Fig. 1). For both the adducted and unadducted forked-duplex
(20 bp) substrates, WRN exonuclease activity at the blunt end
of the DNA substrate was minimal (2%) as evidenced by the
appearance of an intact released oligonucleotide on native gels
(Fig. 1A) and confirmed by analysis of products on urea-dena-
turing gels (data not shown). Similar DNA unwinding of sub-
strate 1-unadducted by an exonuclease-defective mutant WRN
protein (WRN-E84A) was also observed (data not shown).
These results are consistent with a previous observation that
displacement of short (16 and 22 bp) duplex tracts by WRN
helicase activity is more rapid than digestion by the WRN
exonuclease activity (51).
Significant inhibition of WRN helicase activity by all four
BcPh DE adducts was detected at all of the WRN concentra-
tions tested, and the extent of helicase inhibition depended on
the stereochemistry of the specific adduct (Fig. 1). Notably, the
cis-opened adducts inhibited WRN unwinding more effectively
than the trans-adducts (Fig. 1B). This difference was statisti-
cally significant at WRN protein concentrations of 2.4 and 4.8
nM. At a WRN concentration of 2.4 nM (Fig. 1B), the 5-cis-S
adduct profoundly inhibited helicase activity resulting in only
2% of the substrate unwound compared with 23% of the 1-un-
adducted substrate. In comparison, the 3-trans-S substrate
was unwound to an extent of 8%. At 4.8 nM WRN, 47% of the
1-unadducted substrate was unwound, whereas 31 and 14% of
the 2-trans-R and 4-cis-R substrates, respectively, were un-
wound. Similarly, WRN unwinding of 22 and 11% was observed
for the 3-trans-S and 5-cis-S-adducted substrates, respectively.
These results indicate that the orientation (cis/trans) of the
hydroxyl group at C-2 relative to the adenine 6-amino group at
C-1 of the adducts had a significant effect on WRN helicase
activity.
Absolute configuration (S/R) of the adducts at C-1 deter-
mines to which side (3 or 5) of the alkylated dA that the
hydrocarbon intercalates. For substrates 1–5, the adducts with
S configuration, i. e. oriented toward the 3 end of the modified
strand, are oriented toward the approaching helicase, whereas
adducts with R configuration are oriented in the opposite di-
rection, away from the approaching helicase. The adducts with
S configuration exerted slightly greater inhibition of WRN
helicase activity compared to adducts with the R configuration
at 2.4 and 4.8 nM WRN (Fig. 1B). However, the differences are
not statistically significant, indicating that for adducts on the
strand on which helicase translocates the effect of orientation
relative to the DNA strand was unimportant, particularly
when compared with the effect of relative stereochemistry of
the base and hydroxyl group on the adducts.
Orientation Effects of BcPh DE Adducts on WRN Helicase
Activity Are Strand-specific and Stereospecific—We next tested
the same WRN concentrations used for substrates 1–5 on the
helicase substrates 6–10 in which the BcPh DE adduct resided
in the displaced strand opposite to the strand on which WRN
translocates. As observed for substrates 1–5, the percent of
duplex DNA substrate unwound was dependent on WRN heli-
case concentration for these five substrates (Fig. 2). For all five
substrates of this class, the intact oligonucleotide was released
with minimal degradation from the blunt end by WRN exonu-
clease as observed on native gels and confirmed on urea-dena-
turing gels (data not shown). The percent displacement of 6-un-
adducted by WRN was 3.5-fold greater than 1-unadducted at
1.2 nM WRN concentration (Figs. 1B and 2). In a previous study
(11), it was shown that WRN unwound a forked duplex with a
longer 3-single-stranded DNA tail more efficiently than a sub-
strate with a shorter 3-single-stranded DNA tail, consistent
with the difference between helicase activity on 1-unadducted
with a 5-nucleotide 3 tail and 6-unadducted with a 25-nucle-
otide 3 tail.
WRN helicase activity on DNA substrates 7-trans-R, 9-cis-R,
and 10-cis-S was inhibited compared with the 6-unadducted
control substrate at all of the WRN concentrations tested (Fig.
2). At 1.2 nM WRN, 2.4-fold inhibition of WRN helicase activ-
ity on 7-trans-R, 9-cis-R, and 10-cis-S was detected compared
with 6-unadducted (Fig. 2). At 2.4 nM WRN, helicase activity
was reduced 1.7- or 2.7-fold for 7-trans-R and 9-cis-R, respec-
tively. In contrast, WRN unwinding of 8-trans-S was not af-
fected at any helicase concentration. Thus, the WRN helicase is
inhibited by cis-BcPh DE adducts on the displaced strand,
although less so than by the same adducts on the opposite
strand along which WRN translocates. The enzyme shows little
or no discrimination between the cis-R and cis-S diaste-
reomers. In contrast, the unwinding activity is unaffected by
the trans-S adduct on the displaced strand but inhibited by the
trans-R adduct. In substrates 6–10, the R adduct is interca-
lated toward the 5 end of the displaced strand and is thus
oriented toward on the 3 end of the strand on which the
TABLE II
DNA substrates
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helicase is approaching (cf. Table II). The lack of inhibition of
WRN helicase activity by the 8-trans-S substrate suggests that
the trans-BcPh DE adduct residing in the strand opposite to
the one on which WRN translocates only hinders WRN helicase
activity when the adduct is oriented toward the advancing
helicase.
WRN Is Not Trapped by BcPh DE-modified DNA—Previous
studies have suggested that helicases are sequestered by DNA
molecules containing various types of covalent lesions (for re-
view, see Ref. 52). If sequestration by the present DE adducts
in DNA occurs, preincubation of the WRN helicase with unla-
beled single-stranded or forked-duplex DNA containing an ad-
duct should trap WRN and prevent it from unwinding a labeled
but unadducted forked-duplex tracker substrate. Based on the
result that WRN is most significantly inhibited by the cis-S dA
adduct residing in the strand on which the enzyme translo-
cates, we chose this substrate to examine for potential WRN
helicase sequestration.
When WRN was preincubated with either the adducted or
unadducted single-stranded oligonucleotide, little to no inhibi-
tion of WRN helicase activity on the 11-tracker substrate was
observed at any level of oligonucleotide tested (up to a 50-fold
excess) (Fig. 3, A and C). In contrast, both the 1-unadducted
and 5-cis-S forked-duplex DNA inhibited unwinding of the
tracker duplex (Fig. 3, B and D). The ability of forked duplex
but not single-stranded DNA to inhibit WRN helicase activity
on a tracker substrate indicates that WRN preferentially rec-
ognizes or binds the forked structure. This result is consistent
with the significantly increased helicase activity of WRN on a
duplex substrate with 3- and 5-single-stranded DNA tails
compared with a similar substrate flanked by only one single-
stranded DNA tail (11). Preincubation of WRN with 100 fmol of
the forked-duplex DNA molecules 1-unadducted and 5-cis-S
resulted in a moderate decrease of WRN helicase activity. At
higher levels of the 1-unadducted and 5-cis-S forked-duplex
DNA molecules, WRN helicase activity on the 11-tracker sub-
strate was inversely related to the amount of competitor DNA
present in the preincubation step. At 200 fmol of either 1-un-
adducted or 5-cis-S competitor forked duplexes, DNA unwind-
ing of the 11-tracker helicase substrate was approximately 55%
of that observed in the absence of competitor duplex substrate,
and at the highest level (500 fmol) of either 1-unadducted or
5-cis-S, unwinding of the tracker had decreased by 80%.
Notably, however, despite the observation (Fig. 1) that WRN
helicase is significantly less active in unwinding the 5-cis-S
forked duplex compared with the 1-unadducted substrate, pre-
incubation with either of these two substrates resulted in an
equal extent of inhibition of helicase activity on the 11-tracker
(Fig. 3E). This result suggests that WRN was not preferentially
sequestered by the forked-duplex molecule bearing the cis-S
BcPh adduct relative to unadducted DNA.
WRN ATPase Activity in the Presence of Forked Duplex DNA
Effectors—Because WRN ATP hydrolysis fuels DNA unwind-
ing by the helicase, the inhibitory effect of the 5-cis-S BcPh
adduct on WRN helicase activity raised the question of whether
WRN ATPase activity might also be inhibited on binding of
adducted DNA relative to unadducted DNA. To address this
possibility, the initial rate of ATP hydrolysis was determined in
the presence of the 1-unadducted and 5-cis-S substrates (Fig. 4
and Table III). For both the 1-unadducted and 5-cis-S forked
duplexes, the dependencies of ATP hydrolysis rates on the
concentrations of DNA effector from 10 to 200 nM were very
FIG. 1. Inhibition of WRN helicase
activity by a single BcPh DE adduct
positioned in the strand on which
WRN translocates is dependent on
the stereochemistry of the adduct.
Panel A, reaction mixtures (20 l) con-
taining 10 fmol of the indicated forked-
duplex DNA substrate and specified con-
centrations of WRN were incubated at
37 °C for 15 min under standard condi-
tions. Products were resolved on native
12% polyacrylamide gels. Phosphorim-
ages of typical gels are shown. For each
gel: lane 1, no enzyme (NE); lane 2, 0.6 nM
WRN; lane 3, 1.2 nM WRN; lane 4, 2.4 nM
WRN; lane 5, 4.8 nM WRN; lane 6, heat-
denatured substrate control. Panel B, per-
cent displacement from panel A (mean
value  S.D. of at least three experi-
ments) indicated by error bars.
FIG. 2. Inhibition of WRN helicase activity by a single BcPh
adduct positioned in the strand that WRN displaces depends on
stereochemistry and orientation of adduct. Reaction mixtures (20
l) containing 10 fmol of the indicated forked-duplex DNA substrate
and specified concentrations of WRN were incubated at 37 °C for 15 min
under standard conditions. Percent displacement (mean value  S.D. of
at least three experiments) indicated by error bars.
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similar (Fig. 4). The concentrations of forked-duplex DNA re-
quired to achieve the half-maximal rate of ATP hydrolysis (Keff)
for 1-unadducted and 5-cis-S substrates were 25 and 21 nM,
respectively (Table III). The turnover rate constants (kcat) for
initial rates of ATP hydrolysis measured in the plateau region
(200 nM forked-duplex DNA) were 75 and 62 min1 for 1-un-
adducted and 5-cis-S BcPh DNA effectors, respectively. These
kcat values are in the same range as previously published
values for WRN ATP hydrolysis using single-stranded DNA
oligonucleotide effectors (43) under different reaction condi-
tions. The similar Keff and kcat values for WRN ATP hydrolysis
using BcPh DE-modified or unmodified forked-duplex mole-
cules indicate that the presence of the BcPh DE adduct did not
alter the allosteric effect of the bound DNA molecule on WRN
ATP hydrolysis.
Effect of a BcPh Adduct on BLM and UvrD Helicase Ac-
tivity—The inhibition of WRN helicase activity by the cis-S
BcPh adduct positioned in the strand on which WRN translo-
cates raised the question whether other 3–5-DNA helicases
would be similarly affected or whether the inhibition was
unique to WRN. Therefore, we tested BLM helicase, another
human enzyme that is also a member of the RecQ family, and
E. coli UvrD helicase, a member of Superfamily 1, on selected
DNA substrates used for the WRN helicase characterization.
Two concentrations of BLM (2.6 and 5.2 nM), which were
similar to the highest concentrations of WRN used, were ex-
amined. In the presence of 2.6 nM BLM, 19% 1-unadducted
substrate was unwound by BLM, whereas only 8% 5-cis-S DNA
substrate was unwound, a 2.4-fold reduction (Fig. 5A). At 5.2
nM BLM, 34% 1-unadducted substrate was unwound, whereas
15% 5-cis-S was unwound, a 2.3-fold reduction in BLM unwind-
ing (Fig. 5A). Thus, BLM helicase activity was significantly
inhibited by the presence of the cis-S BcPh adduct in the strand
of the DNA substrate on which the helicase translocates. How-
ever, the inhibition of BLM helicase activity in the presence of
this adduct was not as great as that observed (Fig. 1B) for WRN
helicase activity (4.3–11.5-fold).
To address any strand-specific effects of the cis-S adduct on
BLM helicase activity, we tested BLM on 6-unadducted,
9-cis-R, and 10-cis-R substrates. At 2.6 nM BLM, 25% 6-unad-
ducted substrate was unwound compared with 28% 9-cis-R and
24% 10-cis-S, respectively (Fig. 5B). This lack of inhibition of
BLM by these two substrates was clearly in contrast to the
2.7-fold reduction of WRN helicase activity by the 9-cis-R sub-
FIG. 3. WRN is sequestered on BcPh DE-modified or unmodi-
fied forked-duplex DNA molecules. Reaction mixtures (20 l) con-
taining 3.6 nM WRN (lanes 2–8) and increasing amounts of indicated
oligonucleotides A (panel A) or E (panel C) (lane 2, 0 fmol; lane 3, 12.5
fmol; lane 4, 25 fmol; lane 5, 50 fmol; lane 6, 100 fmol; lane 7, 200 fmol;
lane 8, 250 fmol; lane 9, 500 fmol) or increasing amounts of indicated
forked duplexes 1-unadducted (panel B) or 5-cis-S (panel D) (lane 2, 0
fmol; lane 3, 12.5 fmol; lane 4, 25 fmol; lane 5, 50 fmol; lane 6, 100 fmol;
lane 7, 200 fmol; lane 8, 400 fmol; lane 9, 500 fmol) were incubated at
37 °C for 3 min under standard conditions. After 3 min, 10 fmol of
radiolabeled 11-tracker helicase substrate was added to each reaction
and incubated for an additional 7 min at 37 °C. Helicase reaction
products were resolved on native 12% polyacrylamide gels. Lane 1, no
enzyme control (NE); lane 10, heat-denatured substrate control. Panel
E, quantitative analysis of WRN helicase data is shown. , oligonucleo-
tide A; E, oligonucleotide E; f, 1-undamaged; , 5-cis-S. Data represent
the mean value  S.D. of at least three experiments indicated by error
bars.
FIG. 4. WRN requires similar concentrations of BcPh DE-mod-
ified and unmodified forked duplex for half-maximal ATP hy-
drolysis activity. DNA-stimulated ATP hydrolysis reactions were as
described under “Materials and Methods” using 55 nM WRN, 0.8 mM
[3H]ATP, and the indicated concentration of 1-unadducted () or 5-cis-S
(E) forked duplex as the DNA effector.
TABLE III
Hydrolysis of ATP by WRN in presence of forked-duplex DNA effectors
ATP hydrolysis reactions were as described under “Materials and
Methods” using 55 nM WRN and ATP at a concentration of 0.8 mM. For
Keff determinations, DNA effector concentrations ranged from 0 to 200
nM (forked-duplex molecules). For kcat determinations, DNA effector
concentration was 200 nM (forked-duplex molecules).
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strate and the 2-fold reduction by the 10-cis-S substrate at the
2.4 nM WRN concentration. At 5.2 nM BLM, 53% 6-unadducted
substrate was unwound compared with 44% 9-cis-R and 10-
cis-S. These results suggest that the unwinding activity of
BLM helicase, in contrast to WRN, is inhibited only very
weakly by a BcPh adduct positioned in the strand opposite to
the one on which helicase translocates.
We next tested UvrD, a 3–5-helicase from Superfamily 1, to
unwind the same helicase substrates (Fig. 6A). At 0.6 nM, UvrD
unwound 16% 1-unadducted substrate compared with 9% of
the adducted substrate 5-cis-S. At a 1.2 nM concentration of
UvrD, the helicase unwound 27% 1-unadducted and 15%
5-cis-S substrates. The greatest inhibition of UvrD unwinding
was observed at the highest UvrD concentration (2.4 nM). At
this concentration, UvrD unwound 66% 1-unadducted sub-
strate but only unwound 25% 5-cis-S substrate (Fig. 6A). Thus,
similar to BLM helicase, UvrD was inhibited (2.0–2.5-fold) by
the cis-S BcPh adduct on the strand on which the helicase
translocates although to a lesser extent than observed for WRN
(4.3–11.5-fold, see above). UvrD was next tested on the helicase
substrates, 6-unadducted as well as 9-cis-R and 10-cis-S, which
have the adduct in the displaced strand. At 0.15 nM, UvrD
unwound 30% 6-unadducted substrate compared with 18%
9-cis-R and 25% 10-cis-S (Fig. 6B). At 0.3 nM UvrD concentra-
tion, the helicase unwound 77% 6-unadducted, 50% 9-cis-R,
and 62% 10-cis-S substrates (Fig. 6B). This inhibition by an
adduct that resides in the strand opposite to the strand on
which the helicase translocates is only slightly less than that
observed with WRN (2–3-fold inhibition) and differs from our
observation with BLM (20% inhibition).
DISCUSSION
We have examined the effects of bulky, well characterized,
intercalating covalent adducts on WRN-catalyzed DNA un-
winding. This is the first reported characterization of DNA
unwinding by a RecQ helicase on duplex substrates harboring
a site-specific covalent DNA modification. By using a set of
duplex DNA substrates containing BcPh DE adducts at dA
with defined stereochemistry, we have shown that WRN heli-
case activity is differentially affected by the relative and abso-
lute configuration of the BcPh DE adduct residing in the dou-
ble-stranded region of the forked-duplex DNA substrates.
WRN unwinding was clearly inhibited (up to 11-fold) by a
cis-S BcPh DE-dA adduct positioned centrally within the 20-bp
duplex in the strand on which helicase translocates. Although
not as dramatically, the same adduct positioned in the duplex
region of the strand that WRN displaces exerted a significant
2.5-fold inhibition of helicase activity. Previous in vitro studies
of the effects of helix-distorting lesions on the action of DNA
helicases have largely suggested that a DNA lesion within a
single strand inhibits DNA helicase activity when the lesion
resides in the strand on which the protein translocates (52). A
classic example of strand-specific inhibition was reported for
Rad3, a 5–3-DNA helicase implicated in nucleotide excision
repair and transcription. Rad3 helicase activity is sensitive to
UV radiation damage in the DNA strand to which it binds and
along which it translocates during the unwinding reaction but
is not affected by UV radiation damage on the opposite strand
(53). Strand-specific inhibition of Rad3 helicase activity was
also observed for duplex DNA substrates containing either
bulky cisplatin adducts that distort the helix or CC-1065-in-
duced lesions that stabilize the helix (54). Strand-specific inhi-
bition of unwinding activity by DNA lesions has also been
observed for DNA helicases involved in DNA replication (for a
review, see Ref. 52). The 1–2 intrastrand d(GpG) cross-link
induced by the antitumor drug cis-diamminedichloroplatinu-
m(II) significantly reduces the unwinding activity of the Herpes
simplex virus type 1-replicative helicase UL9 only when it is
present on the strand along which the protein translocates (55).
The gene 4 protein that is essential for T7 viral replication
translocates 5–3 along single-stranded DNA, and this move-
ment is blocked by the bulky DNA adducts derived from ben-
zo[a]pyrene (56). Benzo[a]pyrene DNA adducts only inhibit
gene 4 helicase activity if they reside in the strand on which the
helicase translocates (57). These in vitro studies suggest that
for a number of helicases, a DNA lesion within a single strand
compromises unwinding activity by preventing protein trans-
location on the strand containing the adduct.
The inhibition of WRN helicase activity by the BcPh DE
adducts in the strand opposite to the one on which WRN trans-
locates suggests that WRN is either sensitive to the adduct on
the displaced strand or the shape and conformation of the DNA
double helix encountered by the helicase during an unwinding
reaction. In this mode, WRN might be sensitive to the aromatic
rings of the intercalated phenanthrene residue and to the tet-
rahydrobenzo-ring projecting into the major groove or both as
well as to more general distortions induced by the adducts in
the DNA helix structure. We had previously investigated the
effects of noncovalent DNA modifications on WRN helicase
activity. Compared with the potent inhibition exerted by the
minor groove binders distamycin and netropsin, WRN was not
very sensitive to the DNA intercalators m-AMSA and actino-
mycin D and displayed only a mild sensitivity to the DNA
intercalators ethidium bromide and mitoxantrone (58). NMR
structural studies of mitoxantrone-DNA complexes suggest
FIG. 5. Effect of BcPh DE adducts on BLM helicase activity. Reaction mixtures (20 l) containing 10 fmol of the indicated forked-duplex
DNA substrate and specified concentrations of BLM were incubated at 37 °C for 15 min under standard conditions. Quantitative analysis of BLM
helicase data is shown. Panel A, 1-unadducted, black column; 5-cis-S, white column. Panel B, 1-unadducted, black column; 9-cis-R, white column;
10-cis-S, gray column. Data represent the mean value  S.D. of at least three experiments indicated by error bars.
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that the compound intercalates between the base pairs as well
as places functional groups (a positively charged amino group
and two hydroxyl groups) in the major groove of B-form double
helical DNA (59). Despite the chemical differences, the nonco-
valent interaction of mitoxantrone with B-form DNA shares
some similarities with the covalent BcPh DE DNA adducts,
which also intercalate between the base pairs and partially
project into the major groove. However, the present covalent
modifiers differ most significantly from non-covalent intercala-
tors in that they cannot dissociate from the single-stranded
portion of the DNA upon partial or complete unwinding. Thus,
the sensitivity of WRN helicase to DNA structural perturba-
tions may be influenced by the type of modification (covalent or
noncovalent) as well as the nature of the perturbation of the
DNA double helix.
The stereochemistry and orientation of the present covalent
adducts also influence DNA unwinding by WRN helicase. For
adducts positioned in the translocated strand, cis-opened BcPh
DE adducts were significantly better inhibitors of WRN heli-
case activity than their trans-opened counterparts. Regarding
orientation, we had hypothesized that WRN helicase activity
might be inhibited to a greater extent by a BcPh adduct posi-
tioned in the direction of the advancing helicase. For the first
group of substrates (1–5) where the adducts reside on the
strand on which the enzyme translocates, the S adducts (3-
trans-S, 5-cis-S) have the hydrocarbon intercalated toward the
3 side of the modified adenine (in the direction of advance of
the helicase), whereas the R adducts (2-trans-R, 4-cis-R) have
the hydrocarbon intercalated in the opposite direction. As pre-
dicted, there appeared to be a slightly greater inhibition by
3-trans-S relative to 2-trans-R and by 5-cis-S relative to 4-cis-R
(Fig. 1B). However, this effect of orientation was very small and
in general was not statistically significant. A more significant
difference was observed between the trans and cis adducts,
such that cis-opened adducts were more inhibitory than trans-
opened adducts. In the second group of substrates (6–10),
which have adducts on the strand that is displaced, the hydro-
carbon of the R adducts (7-trans-R and 9-cis-R) is intercalated
toward the 5 end of the modified strand and points toward the
direction in which the helicase advances. In this series of sub-
strates, the trans-BcPh adducts only inhibited DNA unwinding
when directed toward the advancing helicase (7-trans-R). How-
ever, this effect of orientation was limited to the trans adducts.
Thus, subtle changes in adduct stereochemistry or orientation
can have a significant impact on DNA unwinding catalyzed by
a helicase.
Despite the effective inhibition of WRN helicase activity by a
single cis-S BcPh adduct in the strand along which the helicase
translocates, the adducted forked-DNA duplex (5-cis-S) did not
trap WRN to any greater extent than the unadducted duplex
molecule (1-unadducted). Furthermore, DNA substrates con-
taining the BcPh DE adducts are not degraded to any signifi-
cant extent by WRN exonuclease, which can degrade from the
blunt end of a forked duplex with a long (34 bp) duplex region
(51), again suggesting that WRN protein does not become
trapped on the damaged DNA molecule to provide an opportu-
nity for WRN exonucleolytic digestion. These observations sug-
gest that WRN dissociates as rapidly from the BcPh-modified
DNA molecule as the unadducted DNA molecule. Other DNA
lesions such as those induced by UV light, cisplatin, or diethyl
sulfate (54, 60) have been shown to sequester Rad3, a helicase
that functions during nucleotide excision repair. Similarly, the
essential helicase for T7 replication, gene 4, when allowed to
react with DNA containing a randomly introduced benzo-
[a]pyrene DE adduct on the strand on which the helicase trans-
locates, is sequestered and forms a stable complex with the
modified DNA (56, 57). The inability of a BcPh DE adduct in
the strand on which the enzyme translocates to trap the WRN
helicase suggests a possible difference in the mechanism of
WRN inhibition by this adduct. Although BLM and UvrD he-
licase activities on the same adducted substrate were also
reduced, the inhibition (2–3-fold) was not nearly as profound as
that observed for WRN. This result suggests a difference be-
tween the ability of WRN and the other two 3–5 DNA heli-
cases to unwind the BcPh-modified DNA that may translate to
other types of lesions.
Despite the inhibition of unwinding, the presence of the
BcPh DE adduct did not affect the rate of ATP hydrolysis
relative to the unadducted control. Although it is possible that
a helicase can retain ATPase activity even when sequestered
by an inhibitory drug-DNA complex such as the anionic por-
phyrin N-methyl mesoporphyrin IX (61), in the present case
preferential sequestration of the helicase by the adducted DNA
was not observed (see above). The result showing that the
kinetics of ATP hydrolysis by WRN with control and adducted
DNA are essentially identical indicates that the cis-R BcPh
adduct does not seriously perturb the allosteric interaction that
activates the enzyme for ATP hydrolysis.
FIG. 6. Effect of BcPh DE adducts on UvrD helicase activity. Reaction mixtures (20 l) containing 10 fmol of the indicated forked-duplex
DNA substrate and specified concentrations of UvrD were incubated at 37 °C for 15 min under standard conditions. Quantitative analysis of UvrD
helicase data is shown. Panel A, 1-unadducted, black column; 5-cis-S, white column. Panel B, 6-unadducted, black column; 9-cis-R, white column;
10-cis-S, gray column. Data represent the mean value  S.D. of at least three experiments indicated by error bars.
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Our observations indicate that WRN helicase activity is sig-
nificantly impaired by a single covalent DNA adduct on either
strand although most strongly when the lesion is in the strand
on which the enzyme translocates. This is in contrast to previ-
ous observations with T7 gene 4 helicase (56, 57) that was
inhibited by benzo[a]pyrene DE-modified DNA only when the
modification was on the translocated strand. Also in contrast to
the T7 helicase with a benzo[a]pyrene DE adduct, the intact
forked double-stranded DNA containing a BcPh DE adduct can
readily dissociate from WRN. WRN then becomes available to
bind another DNA substrate rather than stalling at the site of
the lesion in a futile attempt to unwind it. It should be pointed
out, however, that the present BcPh DE adducts were not a
complete block to WRN since some unwinding of the BcPh-
modified forked-duplex substrates occurred at higher WRN
protein concentrations. The ability of WRN to unwind some but
not all of the adducted duplexes may be accounted for by
several factors/mechanisms. 1) In a subset of cases, WRN re-
mains bound to the adducted DNA substrate long enough even-
tually to disrupt the duplex beyond the adduct. 2) Thermal
breathing of the remaining intact duplex (10 bp) beyond the
site of the BcPh lesion results in the slow non-enzymatic dis-
sociation of these partial duplexes into single-stranded form. 3)
Subsequent recruitment of additional WRN molecules at the
site of a stalled helicase facilitates unwinding of the adducted
DNA substrate. Although this study cannot distinguish among
these possibilities, it is reasonable to conclude that despite the
substantial decrease in WRN helicase activity in the presence
of the BcPh DE adducts, the enzyme is not trapped by the
adducted DNA substrate.
BcPh DEs react extensively with dA residues in DNA (37,
38), and the DEs and their resultant adducts induce a variety
of mutations at dA sites in vivo (39, 63–65). These BcPh DE-dA
adducts are of particular significance since they are known to
elude cellular repair processes (66) and thus are highly likely to
be encountered by other DNA-processing enzymes. The cis-R
and trans-S dA adducts are derived from the highly carcino-
genic and mutagenic ()-(1R,2S,3S,4R)-DE enantiomer,
whereas the cis-S and trans-R dA adducts are derived from the
()-(1S,2R,3R,4S)-DE enantiomer, which is less carcinogenic
(27, 40). Differences in the distribution of mutations induced by
specific BcPh dA adducts have been observed (64), suggesting
that the stereochemistry of these BcPh DEs may influence
DNA-metabolic events such as the fidelity of translesion DNA
synthesis (62). Although DNA polymerases are obvious targets,
the ability of PAH-DE adducts in DNA to interact adversely
with other enzymes such as topoisomerases (25, 26) may also
contribute to their carcinogenic effects. Our present findings
that helicases are inhibited by these adducts in a strand-spe-
cific and stereospecific manner suggest a further mechanism
whereby these lesions could contribute to genetic damage and
cell transformation.
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